文献速递前列腺癌

老年(≥75岁)局限性前列腺癌患者的大分割放疗:IPOPROMISE研究的多中心回顾性分析

Hypofractionated radiotherapy in elderly patients (≥75 years) affected by localized prostate cancer: a multicenter retrospective analysis from the IPOPROMISE study.
PubMed 文献 · Prostate Cancer Prostatic Dis · 2025-03-17

基于IPOPROMISE数据库的回顾性分析纳入719例≥75岁局限性前列腺癌患者,2007至2020年接受每日容积影像引导大分割放疗;中位随访4.2年,5年总生存95.6%、癌症特异性生存99.2%、无转移生存97.3%,5年晚期≥2级胃肠道和泌尿生殖道毒性无事件率分别为95.1%和96.7%。

要点

  • 719例≥75岁局限性前列腺癌患者接受每日容积影像引导大分割放疗,中位随访4.2年。
  • 5年总生存95.6%、癌症特异性生存99.2%、无转移生存97.3%。
  • 5年晚期≥2级胃肠道和泌尿生殖道毒性无事件率分别为95.1%和96.7%。

核心结论

  • 作者认为本研究结果是对现有文献的有价值补充,证实放疗在治愈老年适合的局限性前列腺癌患者中具有突出作用。

研究设计与样本

  • IPOPROMISE数据库的多中心回顾性分析,纳入719例≥75岁局限性前列腺癌患者,2007年至2020年接受每日容积影像引导大分割放疗。
  • 生存终点采用Kaplan-Meier生存曲线及单变量和多变量Cox比例风险回归模型分析。

主要发现

  • 诊断时中位年龄78.4岁(IQR 76.8-80.3岁),74%患者改良Charlson共病指数(e-PCCI)为0。
  • 按NCCN风险分组,399例(55.5%)为不利至极高危疾病。
  • 中位随访4.2年(IQR 2.4-6.4年),31/719例(4.3%)患者因任何原因死亡。
  • 5年总生存95.6%(95%CI 93.4-97.1%)、癌症特异性生存99.2%(95%CI 97.9-99.7%)、无转移生存97.3%(95%CI 95.1-98.5%)。
  • 多变量分析中基线PSA和Gleason评分与无转移生存相关;单变量分析中e-PCCI≥2与总生存相关(p=0.02)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Prostate Cancer (PCa) is the second leading cause of cancer death in the elderly (≥75 years). There is currently little data on hypofractionated radiotherapy in older patients affected by localized PCa. We present the long-term results of hypofractionated radiotherapy in elderly patients with localized PCa from the IPOPROMISE database. MATERIALS AND METHODS: retrospective analysis of 719 PCa elderly (≥75 years) patients treated with daily volumetric image-guided hypofractionated radiotherapy between 2007 and 2020. For survival endpoints, we used Kaplan-Meier survival curves and univariate and multivariable Cox's proportional hazards regression models. RESULTS: Median age at PCa diagnosis was 78.4 years (interquartile [IQR], 76.8-80.3 years), 74% of patients had a modified Charlson co-morbidity index (elderly-PCa-CCI, (e-PCCI)) of 0. Based on NCCN risk grouping, 399 patients (55.5%) were affected by unfavorable to very high-risk disease. Median follow-up was 4.2 years (IQR 2.4-6.4 years). 31/719 (4.3%) patients died from any cause. At 5 years, overall survival (OS), cancer-specific survival (CSS), and metastasis-free survival were 95.6% (95% CI 93.4-97.1%), 99.2% (95%CI 97.9-99.7%), and 97.3% (95% CI 95.1-98.5%), respectively. In multivariate analysis, baseline PSA, and Gleason score were associated with MFS. On univariate analysis, e-PCCI ≥ 2 was associated with OS (p = 0.02). The 5-year freedom from late grade ≥2 gastrointestinal (GI) and genitourinary (GU) toxicity were 95.1% (95% CI 93.0-96.5%) and 96.7% (95% CI 93.7-97.1%), respectively. CONCLUSIONS: Our results represent a valuable add-on to the current literature, confirming the prominent role of radiotherapy in the cure of elderly fit patients affected by localized disease.

来源:Prostate Cancer Prostatic Dis,查看原文。版权归原作者所有。

引用

  1. Ingrosso G, Festa E, Caini S, et al. Hypofractionated radiotherapy in elderly patients (≥75 years) affected by localized prostate cancer: a multicenter retrospective analysis from the IPOPROMISE study. Prostate Cancer Prostatic Dis. 2025. PMID: 40097628. doi:10.1038/s41391-025-00962-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。